Spectrum of mutations in biopsy-proven CADASIL: Implications for diagnostic strategies

Archives of Neurology

Volumn 62, Issue 7, 2005, Pages 1091-1094

  Peters, Nils ^a   Opherk, Christian ^a   Bergmann, Tanja ^a   Castro, Mirna ^a   Herzog, Jürgen ^a   Dichgans, Martin ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; NOTCH3 RECEPTOR; CELL SURFACE RECEPTOR; NOTCH RECEPTOR; NOTCH3 PROTEIN, HUMAN; ONCOPROTEIN;

ARTICLE; CADASIL; CONTROLLED STUDY; EXON; GENE IDENTIFICATION; GENE MUTATION; GENETIC COUNSELING; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; BIOPSY; GENETIC SCREENING; GENETICS; NUCLEOTIDE SEQUENCE;

BIOPSY; CADASIL; DNA MUTATIONAL ANALYSIS; EXONS; GENETIC SCREENING; HUMANS; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, NOTCH;

EID: 22844446634     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.7.1091     Document Type: Article

References (14)

1. Dichgans M, Mayer M, Uttner I, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol. 1998;44:731-739.
2. Peters N, Herzog J, Opherk C, Dichgans M. A two-year clinical follow-up study in 80 CADASIL subjects: progression patterns and implications for clinical trials. Stroke. 2004;35:1603-1608.
3. O'Sullivan M, Jarosz JM, Martin RJ, Deasy N, Powell JF, Markus HS. MRI hyperintensities of the temporal lobe and external capsule in patients with CADASIL. Neurology. 2001;56:628-634.
4. Markus HS, Martin RJ, Simpson MA, et al. Diagnostic strategies in CADASIL. Neurology. 2002;59:1134-1138.
5. Joutel A, Favrole P, Labauge P, et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet. 2001;358:2049-2051.
6. Ruchoux MM, Chabriat H, Bousser MG, Baudrimont M, Tournier-Lasserve E. Presence of ultrastructural arterial lesions in muscle and skin vessels of patients with CADASIL. Stroke. 1994;25:2291-2292.
7. Lesnik Oberstein SA, van Duinen SG, van den Boom R, et al. Evaluation of diagnostic NOTCH3 immunostaining in CADASIL. Acta Neuropathol (Berl). 2003;106:107-111.
8. Joutel A, Vahedi K, Corpechot C, et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet. 1997;350:1511-1515.
9. Razvi SS, Davidson R, Bone I, Muir KW. Diagnostic strategies in CADASIL [comment; letter]. Neurology. 2003;60:2019-2020.
10. Joutel A, Monet M, Domenga V, Riant F, Tournier-Lasserve E. Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/Jk signaling pathway. Am J Hum Genet. 2004;74:338-347.
11. Peters N, Opherk C, Zacherle S, Capell A, Gempel P, Dichgans M. CADASIL-associated Notch3 mutations have differential effects both on ligand binding and ligand-induced Notch3 receptor signaling through RBP-Jk. Exp Cell Res. 2004;299:454-464.
12. Mykkanen K, Savontaus ML, Juvonen V, et al. Detection of the founder effect in Finnish CADASIL families. Eur J Hum Genet. 2004;12:813-819.
13. Joutel A, Dodick DD, Parisi JE, Cecillon M, Tournier-Lasserve E, Bousser MG. De novo mutation in the Notch3 gene causing CADASIL. Ann Neurol. 2000;47:388-391.
14. Mazzei R, Conforti FL, Lanza PL, et al. A novel Notch3 gene mutation not involving a cysteine residue in an Italian family with CADASIL. Neurology. 2004;63:561-564.